Kevin M. Brennan is SVP, FINANCE AND ACCOUNTING of Xilio Therapeutics, Inc.. Currently has a direct ownership of 3,197 shares of XLO, which is worth approximately $2,237. The most recent transaction as insider was on Jan 02, 2025, when has been sold 1,803 shares (Common Stock) at a price of $0.98 per share, resulting in proceeds of $1,766. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.2K
n/a 3M change
n/a 12M change
Total Value Held $2,237

Kevin M. Brennan Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 02 2025
SELL
Open market or private sale
$1,766 $0.98 p/Share
1,803 Reduced 36.06%
3,197 Common Stock
Jan 01 2025
BUY
Exercise of conversion of derivative security
-
5,000 Added 50.0%
5,000 Common Stock
KMB

Kevin M. Brennan

SVP, FINANCE AND ACCOUNTING
Waltham, MA

Track Institutional and Insider Activities on XLO

Follow Xilio Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XLO shares.

Notify only if

Insider Trading

Get notified when an Xilio Therapeutics, Inc. insider buys or sells XLO shares.

Notify only if

News

Receive news related to Xilio Therapeutics, Inc.

Track Activities on XLO